Menarini Group and Radius Health Announce Positive Phase 3 Top...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FLORENCE, Italy and BOSTON, Oct. 21, 2021 /PRNewswire-AsiaNet/ -- - Study met both primary endpoints in patients with ER+/HER2- advanced or mBC- Elacestrant becomes the first oral SERD with positive topline results inpivotal study as a monotherapy versus SoC for the treatment of ER+/HER2-advanced or mBC
...
Authors: LATEST ASIANET NEWS RELEASES